Rocket Pharmaceuticals' CEO Dr. Gaurav Shah On FDA's Clinical Holds On Gene Therapy Trials
Source: Cell & Gene
Rocket Pharmaceuticals CEO Dr. Gaurav Shah offers his take on why gene therapy developers have been plagued by clinical holds, whether the FDA’s AAV-focused CTGTAC meeting's takeaways will hold up throughout 2022, and more.
This website uses cookies to ensure you get the best experience on our website. Learn more